Antidepressants can differ widely in how they physically affect the body, including around a 4 kg difference in weight change between certain drugs (approximately 2.5 kg weight loss from agomelatine and 2 kg weight gain […]
The U.S. Food and Drug Administration (FDA) announced that it will fast-track review of nine experimental drugs.This article was originally published on MedicalXpress.com
Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly lower one-year mortality, especially those also diagnosed with obstructive sleep apnea (OSA), according to a study presented at CHEST […]
For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 inhibitor (SGLT2-i) slows nodule growth and reduces the need for surgical interventions, according to a study presented at CHEST 2025, the […]
According to a recent study, 44% of people with chronic conditions who responded to a population-based survey experienced medication-related burden (MRB). The burden was most common among people with diabetes, heart disease, rheumatic disease or […]
An innovative new pill could soon offer a new and affordable weight management treatment, following a successful clinical trial involving University of Bristol researchers. The results are published in a paper titled “A randomized, double-blind, […]
The Trump administration announced that Boston-based drugmaker EMD Serono will lower the price of one of its leading fertility drugs as part of a push to make in vitro fertilization (IVF) more affordable.This article was […]
About one-third of patients with focal epilepsy, a common form of the neurological disorder, are believed to respond poorly to available therapies. Yet they too may eventually see improvement, if not total relief, from their […]
Current NHS policies designed to improve care for people taking multiple medicines may not be effective, according to new research.This article was originally published on MedicalXpress.com
The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by researchers at The University of […]
© 2025 SimplyWell.ca